GlassScriptPhysician profile
Alexandra Mikhael
NPI 1053795484
$1,559.56
in general payments reported to CMS, 2019-2025
15 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $105 · 2022: $236 · 2023: $230 · 2024: $206 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $586.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $265.19 | 2022-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $156.57 | 2024-2025 | Minimed 780g |
| Advanced Accelerator Applications | $124.89 | 2019 | |
| Tandem Diabetes Care, INC. | $93.12 | 2020 | |
| Ascendis Pharma Endocrinology INC | $86.43 | 2023 | |
| Insulet Corporation | $58.71 | 2023-2025 | Omnipod, Omnipod |
| Amryt Pharma Holdings LTD | $55.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $36.36 | 2019 | |
| Corcept Therapeutics | $21.94 | 2025 | Korlym |
| Beta Bionics, INC. | $17.32 | 2024 | Ilet Bionic Pancreas |
| Lilly USA, LLC | $16.88 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $16.04 | 2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $12.36 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Mikhael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.